Cargando…

COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients

The role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 (COVID-19) in immunosuppressed individuals remains controversial. We describe the course of COVID-19 in patients who had received anti-CD20 therapy within the 3 y...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasten, Mary J., Lahr, Brian D., Parisapogu, Anusha, Yetmar, Zachary A., O’Horo, John C., Orenstein, Robert, Moreno Franco, Pablo, Razonable, Raymund R., Vergidis, Paschalis, Shah, Aditya S., Enzler, Mark J., Inwards, David J., Bauer, Philippe R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692159/ https://www.ncbi.nlm.nih.gov/pubmed/38040756 http://dx.doi.org/10.1038/s41598-023-48145-x

Ejemplares similares

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
por: Yetmar, Zachary A, et al.
Publicado: (2022)

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2021)

2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
por: Yetmar, Zachary, et al.
Publicado: (2018)

Diagnostic Methods and Risk Factors for Severe Disease and Mortality in Blastomycosis: A Retrospective Cohort Study
por: O’Dowd, Timothy R., et al.
Publicado: (2021)

Cryptococcus Species Other Than Cryptococcus neoformans and Cryptococcus gattii: Are They Clinically Significant?
por: Cano, Edison J, et al.
Publicado: (2020)

1691. Cryptococcus Species Other than C. neoformans and C. gattii: Are They Clinically Significant?
por: Cano Cevallos, Edison J, et al.
Publicado: (2019)

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
por: Ordaya, Eloy E, et al.
Publicado: (2022)

Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis
por: Ordaya, Eloy E., et al.
Publicado: (2023)

Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
por: Ripoll, Juan G., et al.
Publicado: (2022)

Clinical Guidance and the Delivery of Care for Patients With Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2020)

Factors Associated with Infectious Diseases Fellowship Academic Success
por: Khodadadi, Ryan B., et al.
Publicado: (2023)

290. Hepatitis E Virus Serostatus: A Retrospective Assessment of Demographics and Comorbidities to Assess High-risk Populations
por: Stone, Eric C, et al.
Publicado: (2019)

COVID-19 in patients with B cell immune deficiency
por: Vergidis, Paschalis, et al.
Publicado: (2022)

Avoiding a Medical Education Quarantine During the Pandemic
por: Suh, Gina A., et al.
Publicado: (2020)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Effect of time and titer in convalescent plasma therapy for COVID-19
por: de Candia, Paola, et al.
Publicado: (2021)

Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19
por: Yetmar, Zachary A., et al.
Publicado: (2021)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

Integrating Infectious Diseases and Preventive Medicine Specialties Into 1 Division: Experience of an Academic Medical Center
por: Murad, M. Hassan, et al.
Publicado: (2023)

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2021)

2676. Effect of β-Lactam Allergy on Appropriateness of Antibiotic Use in Patients with Febrile Neutropenia
por: Yetmar, Zachary A, et al.
Publicado: (2019)

The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
por: Fisher, David L., et al.
Publicado: (2021)

Use of convalescent plasma in COVID‐19 patients with immunosuppression
por: Senefeld, Jonathon W., et al.
Publicado: (2021)

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
por: O’Horo, John, et al.
Publicado: (2022)

Left Ventricular Assist Device: Review of Antimicrobial Prophylaxis Strategies and Incidence of Infections at a Tertiary Care Center 12-Year Experience
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Comparison of Standardized Cytomegalovirus (CMV) Viral Load Thresholds in Whole Blood and Plasma of Solid Organ and Hematopoietic Stem Cell Transplant Recipients with CMV Infection and Disease
por: Dioverti, M Veronica, et al.
Publicado: (2017)

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
por: Razonable, Raymund R.
Publicado: (2011)

2169. Map the Gap: A Novel Approach Using Big Data to Determine the State of the Infectious Diseases Workforce and Fecal Transplant Centers with Regards to Clostridium Difficile Infection
por: Shah, Aditya, et al.
Publicado: (2018)

475. Does Metabolite Matter? Defining Target Itraconazole and Hydroxy-itraconazole Serum Levels for Blastomycosis
por: Hess, Danielle, et al.
Publicado: (2022)

Strangles, convalescent Streptococcus equi subspecies equi M antibody titers, and presence of complications
por: Delph, Katherine M., et al.
Publicado: (2018)

Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19
por: Fazeli, Alieh, et al.
Publicado: (2022)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
por: Temesgen, Zelalem, et al.
Publicado: (2020)

COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response
por: McDyer, John F., et al.
Publicado: (2023)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis
por: Wagner, Tyler, et al.
Publicado: (2020)

Research Response to SARS-CoV-2/COVID-19
por: Burger, Charles D., et al.
Publicado: (2020)

Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers
por: Bäuerl, Christine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lgp1h5ddav7fpb7umkqqek5eun